The document provides an overview of Pfizer Inc., including its business segments, geographic reach, goals, mission/values, history, strategy, external environment analysis, internal environment analysis, and recommendations. It analyzes Pfizer's pharmaceutical, animal health, and corporate/other business segments. Key points include Pfizer operating in over 150 countries, goals of growing in emerging markets and optimizing its patent-protected portfolio, and an analysis of its competitive environment and internal financial performance compared to rivals. One recommendation is for Pfizer to focus on emerging markets like Asia, China, and India.
Indian pharmaceutical industry organisational structure & strategiesPankaj Gaurav
Strategic Implementation & control Project Report on organizational structure and strategies adopted by prominent players in Indian pharmaceutical industry
6. Analysed the core values, mission and vision statement, resources and capabilities,
stakeholder analysis and engagement, organisation culture of Pfizer. This project report explains the current status of Pfizer in Ireland and future business strategy for business growth. By analyzing PESTEL and SWOT, the report provides a recommendation for the future business strategy for Pfizer to reduce weaknesses in the market.
Strategic Management Case of Pfizer. From text book by David, Fred R. "Strategic Management Concepts & Cases",13 th Ed. Assignment on Strategic Management Class in Universitas Tarumanegara Post Graduate class.
This presentation is brief introduction of Pharma Market and work pattern of MNCs (GSK is taken as example).This presentation was given by Faheem Siddiqui in Entrepreneur Conference at MBBS campus-Dadu of Sindh University on 09th October-13
GlaxoSmithKline (GSK) is a British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London.
Pharmaceuticals Industry Analysis with analysis of Top notch Companies in pharmaceuticals viz. Sun pharma, Lupin, Dr. Reddy's Laboratory, Cipla, Aurobindo Pharma to identify opportunity to invest in equity share of these companies.
Merck & co., inc. barclays final 3-10-2015Marcel Brussee
What does Merck's $10B buyback plan say about pharma M&A?
Adding $10 billion to its stock buyback program might mean Merck & Co. ($MRK) wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But The Wall Street Journal sees a different possibility--one the rest of the industry might want to pay attention to.
Source: http://www.fiercepharma.com/story/what-does-mercks-10b-buyback-plan-say-about-pharma-ma/2015-03-26?utm_campaign=SocialMedia
Merck’s Supply Chain Collaboration with Contract Manufacturers and Direct Sup...SAP Ariba
More OEMs are working closely with their suppliers across planning, manufacturing, and logistics functions. Join this session to learn how one of the world’s leading pharmaceutical companies collaborates with key contract manufacturers to engage in constraint-based planning. This requires collaboration on manufacturing work orders, batch and WIP data, and inventory consumption information to ensure full OEM/contract manufacturer alignment on demand, quality, yields, and inventory levels.
Indian pharmaceutical industry organisational structure & strategiesPankaj Gaurav
Strategic Implementation & control Project Report on organizational structure and strategies adopted by prominent players in Indian pharmaceutical industry
6. Analysed the core values, mission and vision statement, resources and capabilities,
stakeholder analysis and engagement, organisation culture of Pfizer. This project report explains the current status of Pfizer in Ireland and future business strategy for business growth. By analyzing PESTEL and SWOT, the report provides a recommendation for the future business strategy for Pfizer to reduce weaknesses in the market.
Strategic Management Case of Pfizer. From text book by David, Fred R. "Strategic Management Concepts & Cases",13 th Ed. Assignment on Strategic Management Class in Universitas Tarumanegara Post Graduate class.
This presentation is brief introduction of Pharma Market and work pattern of MNCs (GSK is taken as example).This presentation was given by Faheem Siddiqui in Entrepreneur Conference at MBBS campus-Dadu of Sindh University on 09th October-13
GlaxoSmithKline (GSK) is a British multinational pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in Brentford, London.
Pharmaceuticals Industry Analysis with analysis of Top notch Companies in pharmaceuticals viz. Sun pharma, Lupin, Dr. Reddy's Laboratory, Cipla, Aurobindo Pharma to identify opportunity to invest in equity share of these companies.
Merck & co., inc. barclays final 3-10-2015Marcel Brussee
What does Merck's $10B buyback plan say about pharma M&A?
Adding $10 billion to its stock buyback program might mean Merck & Co. ($MRK) wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But The Wall Street Journal sees a different possibility--one the rest of the industry might want to pay attention to.
Source: http://www.fiercepharma.com/story/what-does-mercks-10b-buyback-plan-say-about-pharma-ma/2015-03-26?utm_campaign=SocialMedia
Merck’s Supply Chain Collaboration with Contract Manufacturers and Direct Sup...SAP Ariba
More OEMs are working closely with their suppliers across planning, manufacturing, and logistics functions. Join this session to learn how one of the world’s leading pharmaceutical companies collaborates with key contract manufacturers to engage in constraint-based planning. This requires collaboration on manufacturing work orders, batch and WIP data, and inventory consumption information to ensure full OEM/contract manufacturer alignment on demand, quality, yields, and inventory levels.
This presentation was given by LinkedIn CEO, Jeff Weiner, at the Morgan Stanley Technology, Media & Telecom Conference 2014 in San Francisco, California on Monday, March 3, 2014. It outlines LinkedIn's value propositions for our members and customers, as well as detailing the vision of LinkedIn to create economic opportunity for all professionals in the world & the development of the Economic Graph.
Follow our new Economic Graph Showcase Page at: https://www.linkedin.com/company/linkedin-economic-graph
This update on Mergers & Acquisitions, covering the full year of 2016, is based on publicly available information.
For more information: http://www.mckinsey.com/business-functions/strategy-and-corporate-finance/our-insights/m-and-a-2016-deal-makers-catch-their-breath
Strategic Management project on Johnson & Johnson Shobhita Dayal
This presentation talks about the complete framework of the strategic planning of the Johnson & Johnson company. All the topics of strategic management course is been covered, in this ppt starting from SWOT, Strategic Map, External Factor Analysis, and all other major strategic tools.
What strategies should be employed to win in Biosimilars?Santhosh R
What are the key strategies to win in biosimilars market? What should be your plan for payers, physicians, and launch? What should be the focus for pharmaceutical / biosimilar companies?
Key Takeaways -
- There is a need for a holistic approach to succeed in this market environment
- Many biologics are administered by physicians; therefore, more emphasis will have to be directed at the physicians than was the case with small-molecule generics
- Carefully constructed incentive from public and private payers / PBMs could boost biosimilar utilization significantly
- Companies need to instill confidence & awareness in patients just like they do with other stakeholders
- Launch biosimilars in emerging markets before developed markets to develop strong post-marketing data
- Manufacturing biosimilars requires scientific expertise and experience
- Success Checklist
Early asset development and commercialization: Partnering for successCello Health
To be successful in developing an asset you have to identify the need and define the commercial value early on in the development process, as well as revisiting and refining the value as you progress through the phases of development. This means understanding what else is coming onto the market from a competitive perspective and the clinical relevance from a patient perspective. Being mindful about value throughout development is also important because, at each phase more investment will be needed, especially in smaller companies. Often times the need for investment results in a licensing agreement or a partnership.
This is a follow up webinar to "The value of early asset development and commercialization." The slides take a deep dive into how to find the right partner for developing and commercializing your asset.
Presentation on current state of pharmaceutical drug research and ideas for change. It addresses how the pharmaceutical industry, NIH, Government, HealthCare Law, OIG, Public Health
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
Market Access 101: Connecting Access Challenges to Brand OpportunitiesOgilvy Health
Last week, our payer marketing team hosted their inaugural All Access Festival event in our NJ headquarters. This rock concert-inspired event gave our colleagues an inside look at fundamental elements of optimizing market access strategies. Take a look at the presentation chock-full of insights from this event.
Presentation made by Ilyssa Levins at NYU on October 5, 2011 to the Master's Program class of "Public Relations Specialties," taught by PR veteran Saralie Slonsky.
In the 35 slides included here, Ilyssa describes her career path and the industry itself.
She founded her company, Center for Communication Compliance, in 2008 which offers pharmaceutical and medical device companies training and certifications in regulatory compliance.
www.communicationcompliance.com
For more information and specific PR case histories, contact Ilyssa at ilevins@communicationcompliance.com
Class Description: http://www.scps.nyu.edu/course-detail/PRCC1-GC2220/20113/public-relations-specialties
Overview of aspects of pharma's value added services and its primary aspects to deliver them.
Learn what others do and reflect how it's an opportunity for your pharma company..
14. Strategy Diamond How will we get there? Internal Development? How will we compete? On Cost? Via Differentiation (what unique features are included)? What businesses will we be in? Products/Services, Regions, Customers What will be our speed and sequence of moves? How will achieve our competitive position? How are cost advantages generated (scope economies)? How are unique attributes created & delivered? Overview External Internal Recommendations NPV Arenas Vehicles Staging Differentiators Economic Logic
15.
16.
17.
18.
19.
20.
21.
22.
23.
24. Industry Life Cycle “ Shakeout” Phase- growth rates, intense rivalry, margins fall, inferior products with increasing costs and processes cause a decline Goal: sustain and strengthen position within specific business segments, Increase customer loyalty and cash flows Overview External Internal Recommendations NPV